Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Core Points - Krystal Biotech, Inc. will report its fourth quarter and full year 2024 financial results on February 19, 2025, before U.S. market opens [1] - A conference call and webcast will be hosted by the company's management at 8:30 am ET on the same day to discuss the financial results and provide a business update [1] Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines for diseases with high unmet medical needs [3] - The company's first commercial product, VYJUVEK®, is the first-ever redosable gene therapy and the first FDA-approved medicine for treating dystrophic epidermolysis bullosa [3] - The company is advancing a robust pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3]